Lung Fibrosis clinical trials

Explore recruiting lung fibrosis clinical trials.

Recruiting lung fibrosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lung Fibrosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibrosis (WHISTLE-PF Trial)

Belgium, Ireland, Germany, Italy, Austria, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

France, Germany, Italy, Spain, Poland, Netherlands +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Proof-of-principle study of inhaled pulmonary surfactant in patients with Idiopathic Pulmonary Fibrosis (INSURF-IPF)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)

Germany, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the treatment of idiopathic pulmonary fibrosis (BEACON-IPF)

Greece, France, Netherlands, Italy, Spain, Czechia +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A double blind, randomised, placebo-controlled trial evaluating the efficacy and safety of nerandomilast over at least 26 weeks in patients with Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

Netherlands, Germany, France, Spain, Italy, Austria +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lung Fibrosis trials by city

Lung Fibrosis in Toronto Lung Fibrosis in Vancouver Lung Fibrosis in Montreal Lung Fibrosis in Calgary Lung Fibrosis in Edmonton Lung Fibrosis in Ottawa Lung Fibrosis in Winnipeg Lung Fibrosis in Quebec City Lung Fibrosis in Hamilton Lung Fibrosis in Kitchener Lung Fibrosis in London Lung Fibrosis in Halifax Lung Fibrosis in New York Lung Fibrosis in Los Angeles Lung Fibrosis in Chicago Lung Fibrosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease